AAD 2020: Expert Offers Guidance on Management of Cutaneous Eruptions from Immune Checkpoint Inhibitors
Early and aggressive treatment can minimize risk of serious sequelae and the need to discontinue therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.